Abiraterone Acetate

證據等級: L5

預測適應症: 0 個

Abiraterone Acetate: From Prostate Cancer to [Awaiting TxGNN Prediction]

One-Sentence Summary

Abiraterone acetate is a CYP17A1 inhibitor indicated for metastatic castration-resistant prostate cancer (mCRPC), registered in Malaysia under 11 authorizations. However, the TxGNN prediction pipeline has not yet generated new indication candidates for this drug — predicted_indications is empty. Without a prediction output, this report serves as a data completeness audit prior to full repurposing evaluation.

Quick Overview

Item	Content
Original Indication	Metastatic castration-resistant prostate cancer (mCRPC) (from general knowledge; NPRA indication text not retrieved)
Predicted New Indication	Not yet generated
TxGNN Prediction Score	Not available
Evidence Level	Not assessable
Malaysia Market Status	✓ Marketed
Number of Registrations	11
Recommended Decision	Hold — critical data gaps block evaluation

Why is This Prediction Reasonable?

No TxGNN prediction is currently available for Abiraterone Acetate (predicted_indications: []). A mechanistic rationale for repurposing cannot be constructed without a target indication.

Currently, detailed mechanism of action data has not been retrieved from DrugBank. Based on publicly available knowledge, Abiraterone Acetate irreversibly inhibits CYP17A1 (17α-hydroxylase/C17,20-lyase), a key enzyme in androgen biosynthesis in the testes, adrenal glands, and within prostate tumour tissue itself. This androgen-depletion mechanism drives its efficacy in hormone-sensitive and castration-resistant prostate cancer.

Once the TxGNN prediction pipeline is executed and a new indication candidate is identified, the mechanistic bridge between CYP17A1 inhibition and the predicted disease can be evaluated here.

Clinical Trial Evidence

Currently no TxGNN-predicted indication is available. Clinical trial evidence cannot be displayed.

Literature Evidence

Currently no TxGNN-predicted indication is available. Literature evidence cannot be displayed.

Malaysia Market Information

The NPRA query returned 11 registered licenses, but individual license details (authorization number, product name, dosage form, approved indication text) were not populated in this Evidence Pack. Please re-run the data extraction with full field retrieval.

Authorization Number	Product Name	Dosage Form	Approved Indication
(Not retrieved)	(Not retrieved)	(Not retrieved)	(Not retrieved)

⚠️ 11 registrations confirmed via NPRA query (2026-03-27), but individual record details require a follow-up extraction pass.

Cytotoxicity

Abiraterone Acetate is an antineoplastic agent (androgen biosynthesis inhibitor for prostate cancer).

Item	Content
Cytotoxicity Classification	Targeted therapy — Hormonal / CYP17A1 inhibitor (not conventional cytotoxic)
Myelosuppression Risk	Low (non-cytotoxic mechanism; myelosuppression not a primary concern)
Emetogenicity Classification	Low
Monitoring Items	Liver function (ALT/AST/bilirubin), serum potassium, blood pressure, fluid retention, serum testosterone and PSA
Handling Protection	Standard oncology handling precautions; does not typically require cytotoxic drug handling protocols under most institutional guidelines, but confirm per local SOPs

Safety Considerations

Please refer to the package insert for safety information.

The Evidence Pack carries DG001 (Blocking): NPRA/TFDA package insert warnings and contraindications have not been retrieved. This gap must be resolved before any safety-gated decision can be made.

Conclusion and Next Steps

Decision: Hold

Rationale: The two most critical inputs for a repurposing evaluation — TxGNN predicted indications and safety/MOA data — are both absent. Proceeding without them would yield an uninformative risk assessment.

To proceed, the following is needed:

[DG001 — Blocking] Retrieve NPRA/TFDA package insert: download the PDF and parse warnings, contraindications, and special population data
[DG002 — High] Query DrugBank API for ABIRATERONE ACETATE to obtain DrugBank ID, confirmed MOA, drug categories, and toxicity data
Re-run TxGNN prediction pipeline — predicted_indications is empty; execute KG + DL prediction steps and populate the Evidence Pack
Re-extract NPRA license details — 11 registrations exist but individual record fields (product name, dosage form, indication text) were not captured; re-query with full field mapping
Once predictions are available, re-generate this report with a target indication and evidence tables
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.